Controlled Human Exposure to Indoor Air, Dust and Ozone

NCT02017782 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2013-12-23

No results posted yet for this study

Summary

The aim of the study is to provide information which may help to improve the quality of the life of persons exposed to indoor environments in Danish dwellings.

The experiment will document if dust and ozone contribute to deterioration of indoor air quality and to the occurrence of symptoms and health effects.

The study is aimed at testing the hypothesis that the presence of ozone potentiate the health and comfort effects of dust exposure in the indoor environment.

Testing this hypothesis will be based on the following questions:

Does house dust and ozone in concentrations frequently encountered in Danish dwellings cause unwanted health effects either by themselves or by interaction?

If so, does the presence of ozone potentiate the expected irritative effects of dust?

The challenge of these hypotheses will be made as a controlled experiment on humans in a climate chamber under controlled exposure conditions.

This controlled human experiment should be able to substantiate the findings from the intervention studies.

Furthermore, they ideally reflect something relevant to the general public and therefore should have maximum public appeal and application possibilities.

Conditions

  • Subjective Discomfort
  • General Mucosal Irritation
  • Acute Changes in Respiratory Outcomes
  • Acute Changes in Cardiovascular Outcomes
  • Changes in Biomarkers

Interventions

DEVICE

Dust

Dust (250-300µg/m3),

DEVICE

Ozone

(0,1ppm ozone),

DEVICE

Dust and Ozone

Active Dust (250-300 ug/m3)+Ozone(0,1ppm)

DEVICE

Placebo (Filtered air)

Placebo treatment (Filtered air \<20 ug/m3)

Sponsors & Collaborators

  • University of Aarhus

    lead OTHER

Principal Investigators

  • Torben Sigsgaard, Professor · University of Aarhus, School of Public Health, Dept. of Environment and Occupational Medicine

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
60 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-04-30
Primary Completion
2013-07-31
Completion
2013-07-31

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02017782 on ClinicalTrials.gov